Alto neuroscience has closed a $60M Series B to develop precision medicine for depression, PTSD, and other mental health conditions.  The company is based in Los Angeles. Alto neuroscience has raised over $100M since its inception in 2019. The company aims to use this Series B funding to boost its clinical trial process. Alto neuroscience uses a technology called Precision Psychiatry Platform. By using this platform, the company can match patients with the right drug by analyzing their genetics, behavioral data, wearable data, etc. The company currently has six clinical trials in the pipeline.